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diture Panel Survey (MEPS) was analyzed. Rasch Rating
Scale model was used. Fit statistic and PC analysis of
residuals evaluated unidimensionality of 21-item scale 
for each group. Item and rating scale functioning were
compared across groups by independent t-tests and 
correlations.
RESULTS: Person separation was 1.93 in OA patients
and 2.40 in RA. For both groups, the item on perceived
mental health had high INFIT/OUTFIT MNSQ (>1.4),
while activity limitation item displayed overﬁt
(INFIT/OUTFIT MNSQ <0.6). Analysis demonstrated
congruent item hierarchies in both conditions. Invariance
in item difﬁculties and rating scale step measures was
revealed by non-signiﬁcant (alpha = 0.05) t-statistic.
CONCLUSIONS: Instrument functioned satisfactorily in
both groups. Nineteen items showed adequate ﬁt with
unidimensional requirements. No conclusive difference 
in interpretation of items or response categories was
observed. Patients with OA and RA demonstrated iden-
tical health functional impairments. Therefore, scale
appears to be applicable and measures equivalently in OA
and RA.
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In clinical trials, etanercept has been shown to improve
health outcomes and functional status. This observational
study was undertaken to evaluate etanercept in a non-trial
(naturalistic) setting.
OBJECTIVE: To analyze the impact of etanercept on
HRQOL and functional status in persons with RA in a
naturalistic setting.
METHODS: 1043 persons with RA and on etanercept
therapy were followed in an observational, longitudinal
study. HRQOL and functional status data was obtained
via mailed questionnaires at baseline and at 6 months.
Vitality and mental health was measured by domain ques-
tions on the Medical Outcomes Study Short Form 36 (SF-
36). Functional outcomes were measured by the Health
Assessment Questionnaire (HAQ).
RESULTS: 82.3% of the sample were women. The mean
age was 54 years. Both the SF-36 vitality and mental
health domain scores had clinically meaningful improve-
ments. The mean score at baseline for vitality was 30.3
units (0–100, 100 = no impairment) and mental health
was 58.0 units. At 6 months, vitality improved by 20.5
units and mental health improved by 13.4 units. 70.6%
of the sample for vitality and 53.3% for mental health
experienced clinically meaningful improvements of at
least 10 units at 6 months. The mean HAQ index at base-
line was 1.54 units (0–3, 3 = greatest disability). At 6
months follow-up, the mean index decreased (improved)
by 0.68 units. At the 6 month follow-up, 77.9% of the
sample experienced a clinically meaningful improvement
in HAQ index of 0.25 units or greater. Additionally,
10.6% achieved a zero HAQ index and 36.9% achieved
an index of 0.5 units or less.
CONCLUSION: In this naturalistic study, etanercept
demonstrated signiﬁcant improvement in HRQOL and
functionality, as measured by the SF-36 and HAQ.
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OBJECTIVES: To utilize WebTV technology to measure
depression in arthritic patients using Center for Epidemi-
ological Studies Depression Scale (CESD-20) and to assess
health related quality of life (HRQOL) using Short Form
36 (SF-36).
METHODS: Random Digit Dialing (RDD) survey 
procedures were used to recruit individuals previously
diagnosed with arthritis (N = 550), drawn from US house-
holds across 44 states. Each participating household was
outﬁtted with a free WebTV and internet connection.
Cut-off scores of <52 and >16 were used on the Mental
Health (MH) subscale of SF-36 and CESD-20, respec-
tively, to identify arthritic patients at risk for clinical
depression.
RESULTS: A response rate of 87% (N = 480) was
achieved following the administration of surveys in
August 2001. Using CESD scores, 16% (n = 76) of the
respondents were found to be at risk for clinical depres-
sion, as opposed to only 4% (n = 19) of the subjects who
scored below the cutpoint on the MH subscale of SF-36.
A strong negative correlation (r = -0.68) was found
between the CESD sum of scores and MH domain scores.
Signiﬁcant differences on the CESD scores were found
between different age groups, for both males and females,
and between groups previously diagnosed with osteo-
arthritis and rheumatoid arthritis.
CONCLUSIONS: While concurrent administration of
SF-36 and CESD-20 in patients with a chronic disease 
is desirable for simultaneous assessment of health status
and depressive symptomatology, conﬂicting results are
possible when the two instruments measure the same 
criterion. SF-36 and CESD-20 lead to differential assess-
ment of depression resulting in a discrepancy in the 
measurement.
